Biden-era abortion by mail rules face key test at appeals court hearing
A federal appeals court is scheduled to consider whether to restore restrictions on mailing mifepristone, an abortion-inducing drug. This legal action tests a biden-era policy criticized for inadequate safety review, which the Trump administration chose not to defend. The hearing in New Orleans involves Louisiana’s efforts to halt shipments of the drug, arguing it undermines its near-total abortion ban. Simultaneously occurring, the Biden administration prefers to await an FDA safety review before imposing restrictions, especially ahead of the midterm elections. The article also includes promotional content from the Washington Examiner urging readers to subscribe for full access to news, analysis, and commentary, highlighting their trusted reporting and offering subscription options.
A federal appeals court will consider on Wednesday whether to restore restrictions on mailing the abortion-inducing drug mifepristone, testing a Biden-era policy that judges have faulted for inadequate safety analysis and the Trump administration has declined to defend on its merits.
The hearing before the 5th U.S. Circuit Court of Appeals in New Orleans comes as Louisiana seeks to stop shipments of the drug that it says undermine its near-total abortion ban. The hearing also puts renewed pressure on President Donald Trump‘s administration, which has asked courts to wait for a Food and Drug Administration safety review rather than impose restrictions before the midterm elections.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
Already a member? Log in
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
